top of page

About Inhalon

Inhalon Biopharma is a clinical-stage biotechnology company developing revolutionary inhaled antibody treatments for acute respiratory infections. 

 

Inhalon is rapidly advancing programs for the treatment of multiple respiratory infections:

  • Respiratory Syncytial Virus

  • Influenza

  • Human metapneumovirus

  • SARS-CoV-2

Because preventative vaccine therapies for acute respiratory infections fail to fully protect people from infection, Inhalon’s breakthrough technology has the potential to address a massive unmet need by treating active infection, directly in the lung.

And, Inhalon's solution is designed to do even more. 

History

History

2018

  • Inhalon Biopharma founded by Sam Lai, Ph.D.

2019

  • Received $500,000 from The Thiel Foundation through Breakout Labs

  • Appointed John Whelan as Chief Executive Officer

2020

  • Raised $3.1Million in Series Seed led by Life Science Angels

2021

  • Awarded $7 Million grant from U.S. Army Medical Research & Development Command (USAMRDC) to study IN-006, an Inhaled "Muco-trapping" Antibody for the Treatment of COVID-19

  • Appointed Jeff Hutchins, Ph.D. as Chief Development Officer

  • Dosed first patient in Phase 1 Study of inhaled IN-006

2022

  • Completed Phase 1 study of inhaled IN-006

  • Raised $5 Million in Series A led by JSR Life Sciences and Life Science Angels

  • Awarded $2 Million grant from National Institutes of Health (NIH) for IND-enabling development of inhaled IN-002, a potential treatment for respiratory syncytial virus (RSV)

  • Released data for the Phase 1 inhaled IN-006 study on medRxiv

  • Awarded $1.7 Million grant from the North Carolina Collaboratory at University of North Carolina at Chapel Hill to Develop IN-007, an Inhaled ACE2-Targeting Therapeutic for SARS-CoV-2

2023

  • Dosed first patient in Phase 1b Study of inhaled IN-006

  • Awarded $1 Million from NIH to support IN-002 for RSV

  • Awarded $6 Million grant from U.S. Army Medical Research & Development Command (USAMRDC) to study IN-007, an Inhaled ACE2-Targeting Therapeutic for SARS-CoV-2

Leadership

0.jpg

President, Chief Executive Officer and Director

0-1.jpg

Founder, Chief Scientific Officer and Director

hutchins.jpeg

Chief Development Officer

Tom.webp

Vice President, Clinical

leadership
board

Board of Directors

0.jpg

President, Chief Executive Officer and Director

0-1.jpg

Founder, Chief Scientific Officer and Director

0-2.jpg

Founding Director

investors

Investors

cvfbuvztoyejmo6q0wff.png
BreakoutLabs_logo.png
Band_of_Angels_(investors)_logo.png
static1_edited.png
BCF-transparent_1x.png
JSR LS Full Color Horizontal Logo 2019OCT62019.png

Partners

logo-MTEC.png
logo-UNC.png
UGAlogo_Formal_FC_MARCM.png
partners
bottom of page